Immucell Corp. (ICCC)
NASDAQ:ICCC
Total Valuation
Immucell has a market cap or net worth of $58.26M. The enterprise value is $60.15M.
Market Cap$58.26M
Enterprise Value$60.15M
Share Statistics
Immucell has 9,046,799 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding9,046,799
Owned by Insiders1.65%
Owned by Institutions3.51%
Financial Efficiency
Immucell’s return on equity (ROE) is -0.04 and return on invested capital (ROIC) is 4.09%.
Return on Equity (ROE)-0.04
Return on Assets (ROA)-0.02
Return on Invested Capital (ROIC)4.09%
Return on Capital Employed (ROCE)0.04
Revenue Per Employee400.64K
Profits Per Employee-15.07K
Employee Count69
Asset Turnover0.65
Inventory Turnover1.75
Valuation Ratios
The current PE Ratio of Immucell is ―. Immucell’s PEG ratio is 0.99.
PE Ratio―
PS Ratio2.01
PB Ratio2.05
Price to Fair Value2.05
Price to FCF45.32
Price to Operating Cash Flow0.00
PEG Ratio0.99
Income Statement
In the last 12 months, Immucell had revenue of 27.64M and earned -1.04M in profits. Earnings per share was -0.12.
Revenue27.64M
Gross Profit11.45M
Operating Income1.65M
Pretax Income-1.03M
Net Income-1.04M
EBITDA4.43M
Earnings Per Share (EPS)-0.12
Cash Flow
In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.
Operating Cash Flow0.00
Free Cash Flow0.00
Free Cash Flow per Share0.00
Dividends & Yields
Immucell pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-0.29
52-Week Price Change19.70%
50-Day Moving Average6.39
200-Day Moving Average6.22
Relative Strength Index (RSI)51.81
Average Volume (3m)20.75K
Important Dates
Immucell upcoming earnings date is May 20, 2026, After Close (Confirmed).
Last Earnings DateMar 4, 2026
Next Earnings DateMay 20, 2026
Ex-Dividend Date―
Financial Position
Immucell as a current ratio of 4.26, with Debt / Equity ratio of 21.09%
Current Ratio4.26
Quick Ratio1.93
Debt to Market Cap0.10
Net Debt to EBITDA0.43
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Immucell has paid 11.00K in taxes.
Income Tax11.00K
Effective Tax Rate-0.01
Enterprise Valuation
Immucell EV to EBITDA ratio is 12.95, with an EV/FCF ratio of 46.87.
EV to Sales2.08
EV to EBITDA12.95
EV to Free Cash Flow46.87
EV to Operating Cash Flow23.19
Balance Sheet
Immucell has $3.81M in cash and marketable securities with $5.71M in debt, giving a net cash position of -$1.90M billion.
Cash & Marketable Securities$3.81M
Total Debt$5.71M
Net Cash-$1.90M
Net Cash Per Share-$0.21
Tangible Book Value Per Share$2.99
Margins
Gross margin is 41.40%, with operating margin of 5.97%, and net profit margin of -3.76%.
Gross Margin41.40%
Operating Margin5.97%
Pretax Margin-3.72%
Net Profit Margin-3.76%
EBITDA Margin16.04%
EBIT Margin5.97%
Analyst Forecast
The average price target for Immucell is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast16.49%
EPS Growth Forecast―